Loading...
A104 COST-EFFECTIVENESS OF INFLIXIMAB BIOSIMILAR FOR THE MANAGEMENT OF CROHN’S DISEASE
BACKGROUND: Infliximab is an anti-TNF therapy with proven efficacy for the induction and maintenance of remission in patients with Crohn’s disease (CD). An infliximab biosimilar, CT-P13 (marketed as Inflectra), has recently been introduced that could potentially result in large cost-savings for this...
Na minha lista:
| Udgivet i: | J Can Assoc Gastroenterol |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Oxford University Press
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6507792/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwy008.105 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|